SEGMENTS (Tables)

9 Months Ended

Sep. 30, 2021

Segment Reporting [Abstract]

SCHEDULE OF SEGMENT INFORMATION

The following table summarizes the Company’s segment information for the following balance sheet dates presented, and for the nine months ended September 30, 2021 and 2020:

	Real Estate			Digital Transformation Technology			Biohealth Business			Other			Total
Nine Months Ended September 30, 2021
Revenue	$	12,026,069		$	-		$	4,919,844		$	-		$	16,945,913
Cost of Sales		(8,291,698	)		-			(218,507	)		-			(8,510,205	)
Gross Margin		3,734,371			-			4,701,337			-			8,435,708
Operating Expenses		(901,236	)		(173,594	)		(3,451,152	)		(8,940,432	)		(13,466,414	)
Operating Income (Loss)		2,833,135			(173,594	)		1,250,185			(8,940,432	)		(5,030,706	)
Other Income (Expense)		(9,063	)		403,000			(33,960,503	)		(53,727,340	)		(87,293,906	)
Net Income (Loss) Before Income Tax		2,824,072			229,406			(32,710,318	)		(62,667,772	)		(92,324,612	)

	Real Estate			Digital Transformation Technology			Biohealth Business			Other			Total
Nine Months ended September 30, 2020
Revenue	$	7,148,786		$	-		$	31,133		$	-		$	7,179,919
Cost of Sales		(5,603,164	)		-			(6,139	)		-			(5,609,303	)
Gross Margin		1,545,622			-			24,994			-			1,570,616
Operating Expenses		(634,254	)		(87,972	)		(388,083	)		(3,424,869	)		(4,535,178	)
Operating Income (Loss)		911,368			(87,972	)		(363,089	)		(3,424,869	)		(2,964,562	)
Other Income (Expense)		(2,646	)		115			(10,211,916	)		433,844			(9,780,603	)
Net Income (Loss) Before Income Tax		908,722			(87,857	)		(10,575,005	)		(2,991,025	)		(12,745,165	)
September 30, 2021
Cash and Restricted Cash	$	7,951,918		$	228,627		$	2,845,805		$	61,914,783		$	72,941,133
Total Assets		42,348,896			1,252,457			18,136,991			113,397,797			175,136,141
December 31, 2020
Cash and Restricted Cash	$	8,150,769		$	158,058		$	1,590,265		$	21,836,387		$	31,735,479
Total Assets		28,954,484			158,160			524,603			78,076,498			107,713,745